Takeda To Acquire Paradigm

Takeda Pharmaceutical Co. (Tokyo: 4502) has agreed to acquire Paradigm Therapeutics Ltd., a Cambridge, UK-based developer of drugs targets identified from the human genome. No financial terms were disclosed for the deal, which is expected to close within the next few weeks. Paradigm has raised nearly $40 million in VC funding since 2000, from firms like Avlar BioVentures, Bio*One Capital, Merlin Biosciences and Technomark Medical Ventures. www.paradigm-therapeutics.co.uk